NanoValent Pharmaceuticals Announces the Publication of US Patent Targeted Polymerized Nanoparticles for Cancer TreatmentHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)NanoValent Pharmaceuticals Announces the Publication of US Patent Targeted Polymerized Nanoparticles for Cancer TreatmentACCESSWIREJanuary 8, 2020ReblogShareTweetShareNanoValent will Deliver a Corporate Presentation at the IvyFON Family Office 2020 Outlook Conference, January 14th in San Francisco during the JP Morgan Healthcare Conference WeekSAN FRANCISCO, CA / ACCESSWIRE / January 8, 2020 / NanoValent Pharmaceuticals, Inc., a development stage cancer focused pharmaceutical company progressing a new class of targeted nanospheres (TNS) based therapies today announced the publication of United States Patent No. 10,369,104 from the U.S. Patent and Trademark Office relating to its application of targeted polymerized nanoparticles in cancer and the invitation to present at the IvyFON Family Office 2020 Outlook Conference on January 14th in San Francisco, California.View Full Release, including press-ready images, quotes, bios, and more.Key TakeawaysNanovalent issued US patent relating to its application of targeted polymerized nanoparticles in cancer.This patent will support our goal of an additional financing effort this year to accelerate the already ongoing pre-IND work for our lead therapeutic in Ewing sarcoma.Company to present at the IvyFON Family Office 2020 Outlook Conference, January 14th in San Francisco.About NanoValent Pharmaceuticals, Inc.NanoValent Pharmaceuticals, Inc., founded in 2006, is a privately-held company focused on the development and commercialization of a new generation of Targeted Nanospheres (TNS). Working in close collaboration with Children's Hospital Los Angeles (CHLA), NanoValent aims to develop superior therapeutics for patients restricted by current treatment options and working with other pharmaceutical companies optimize or expand the utility of additional therapeutics.The company's proprietary platform technology is an important, new, tool that can potentially improve the efficacy and safety of a wide range therapeutic molecules and biologics. The targeting options and flexibility of the platform make potential applications almost limitless. NanoValent's leading drug candidate, NV103 (anti-CD99, irinotecan), is approaching phase I clinical trials with initial validating programs including Ewing Sarcoma, Hepatocellular Carcinoma, Neuroendocrine tumors, Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). Other cancer therapeutic candidates include NV101 (anti-CD99, doxorubicin) and NV102 (anti-CD19, doxorubicin).Funding has come from direct management investment, angel investors and significant grants from the National Science Foundation, the National Cancer Institute and the Montana Chamber of Commerce. Please visit http://www.nanovalent.com for more information.About IVY Family Office NetworkIvy Family Office Network (IVYFON) has been a leading peer to peer family office network since 2005. More than 40,000 investors, family offices and asset allocators have attended their events.IVYFON have run Family Office forums in more than 25 cities around the world and operate on a continual basis in 20 of them.The event types and initiative formats allow IVYFON to provide local family offices forums that restrict attendance by vendors, preserve family office privacy and provide up-to-the minute information on investment themes for attendees. Please visit https://ivyfon.com for more information.CONTACT:Timothy Ennstime@nanovalent.com(925) 719-2143President and CEOSOURCE: NanovalentView source version on accesswire.com: https://www.accesswire.com/572361/NanoValent-Pharmaceuticals-Announces-the-Publication-of-US-Patent-Targeted-Polymerized-Nanoparticles-for-Cancer-TreatmentView photosReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextFacebook Cancels Annual Conference Due to Coronavirus Concerns: 'This Was a Tough Call to Make'People'Dispatches From Elsewhere': a crazy real-life 'game' comes to TVAFPRegulators boost PG&E's wildfire fine to $2.1 billionAssociated PressWould You Live in an Adult Dorm? One Silicon Valley Startup Is Renting Out Shared RoomsHouse BeautifulBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance